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Quality of life in the follow-up of uveal melanoma
patients after CyberKnife treatment
Annemarie Klingensteina, Christoph Fürwegerb, Martin M. Nentwicha,
Ulrich C. Schallerc, Paul I. Foerstera, Berndt Wowrab, Alexander Muacevicb
and Kirsten H. Eibla
To assess quality of life in uveal melanoma patients within
the first and second year after CyberKnife radiosurgery.
Overall, 91 uveal melanoma patients were evaluated for
quality of life through the Short-form (SF-12) Health
Survey at baseline and at every follow-up visit over 2 years
after CyberKnife radiosurgery. Statistical analysis was
carried out using SF Health Outcomes Scoring Software
and included subgroup analysis of patients developing
secondary glaucoma and of patients maintaining a best
corrected visual acuity (BCVA) of the treated eye of 0.5
log(MAR) or better. Analysis of variance, Greenhouse–
Geisser correction, Student’s t-test, and Fisher’s exact test
were used to determine statistical significance. Physical
Functioning (PF) and Role Physical (RP) showed a
significant decrease after CyberKnife radiosurgery,
whereas Mental Health (MH) improved (P = 0.007,
P < 0.0001 and P = 0.023). MH and Social Functioning (SF)
increased significantly (P = 0.0003 and 0.026) in the no
glaucoma group, MH being higher compared with
glaucoma patients (P = 0.02). PF and RP were significantly
higher in patients with higher BCVA at the second follow-
up (P = 0.02). RP decreased in patients with BCVA < 0.5
log(MAR) (P = 0.013). Vitality (VT) increased significantly in
patients whose BCVA could be preserved (P = 0.031).
Neither tumor localization nor size influenced the
development of secondary glaucoma or change in BCVA.
Although PF and RP decreased over time, MH improved
continuously. Prevention of secondary glaucoma has
a significant influence on both SF and MH, whereas
preservation of BCVA affects VT. Emotional stability
throughout follow-up contributes positively toward overall
quality of life. CyberKnife radiosurgery may contribute to
attenuation of emotional distress in uveal melanoma
patients. Melanoma Res 23:481–488 c 2013 Wolters
Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
Uveal melanoma, as the most common primary intraocular
tumor in adults [1], has a reported incidence of 5–7 per
million [2]. Despite local tumor control being achieved in
the vast majority of cases [3], radical surgery in oncology
leading to severe functional and eventually esthetic
harm [4] may result in severe effects on patients’ quality
of life. Enucleation and radiation therapy have different
physiological and psychological effects on the patient and
these will reflect on their quality of life [5,6].
As there is no difference in survival among the various
treatment strategies for uveal melanoma [7], the effect of
the treatment chosen on the quality of life of the patient
should be considered during treatment planning [8].
In the long-term follow-up of the Collaborative Ocular
Melanoma Study group, cumulative all-cause mortality
was 43% among patients in the 125I brachytherapy arm
and 41% in the enucleation arm after 12 years [9].
Five-, 10-, and 12-year rates of death because of
histopathologically confirmed melanoma metastasis were
10, 18, and 21% after brachytherapy and 11, 17, and 17%,
respectively, after enucleation and thus showed no
significant difference [9]. Preservation of vision, and
prevention of recurrence and of side effects should be the
main goals in patient management along with a cosmet-
ically acceptable result. Enucleation is a physically and
psychologically traumatic procedure. To avoid total organ
loss, some patients prefer to conserve their eye [10]. The
presence of a serious disease can cause depression [11]
and compared with other cancer diagnoses and normative
data, high proportions of uveal melanoma patients report
reduced quality of life and major emotional problems 1
year after surgery [10,12,13]. After radiotherapy, fewer
signs of deterioration with a decrease in quality of life
of only 5% have been observed [14]. Tumors of at least
6 mm in thickness remain controversial for suitability
for 106Ru brachytherapy and therapeutic alternatives
include proton beam radiotherapy, transscleral local
resection, endoresection, enucleation, or stereotactic
radiosurgery (as Gamma Knife or CyberKnife) [15].
Current designs and techniques of radiation therapy
need to be explored [16]. First studies on CyberKnife
radiosurgery as a locoregional treatment for uveal
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melanoma showed promising results without serious
acute adverse events [15,17].
Precise assessment of physical, mental, and overall quality
of life may help improve treatment decision in
uveal melanoma patients. Health-related quality-of-life
research is indispensible because it provides insights into
domains not directly observable [18]. The Short-form
(SF-12) Health Survey used in this study assesses
physical as well as mental health component summaries
in a questionnaire containing 12 items. Table 1 shows the
content of the SF-12 used in this study. As enucleation is
a radical intervention leading to functional and esthetic
impairment with an effect on vitality, physical, emotional,
mental health, and social life concepts [19], we have
evaluated quality of life in uveal melanoma patients after
CyberKnife radiosurgery through SF-12.
Methods
Quality of life was assessed through the 4-week recall SF-12
Health Survey in 91 uveal melanoma patients (male :
female = 48 : 43) who had undergone local CyberKnife
radiosurgery between November 2005 and September
2011. Detailed patient characteristics are summarized
in Table 2. Patients included had been evaluated for
radiosurgery treatment eligibility by a dedicated board of
tumor specialists from the University Hospital of Munich
consisting of ophthalmologists, radiation oncologists, and
stereotactic radiosurgeons. CyberKnife radiation was
performed as an outpatient procedure. At first presentation
as well as at every follow-up visit, apart from radiographic
work-up and complete ophthalmological examination
including standardized echography, patients were asked
to complete the standardized SF-12v2 Health Survey
(c 1992, 2000 Health Assessment Lab, Medical Outcomes
Trust and QualityMetric Incorporated, German Version
2.0, 10/03). Informed consent was obtained from all
patients when completing the SF-12. All patients were
archived in a digital database and the surveys were analyzed
retrospectively. They completed at least three surveys [at
baseline visit and after a median of 4 and 15 months (mean
3 and 15 months) after therapy]. Clinical data were
gathered from the original medical files. The mean values
of visual acuity were calculated after transforming the mean
angle of resolution values into log(MAR) values. This study
received the approval of the institutional review board of
Ludwig-Maximilians University, Department of Ophthal-
mology, Munich, Germany, and is in accordance with the
Declaration of Helsinki.
With the SF-12 as a multipurpose short-form, in only
12 questions, summary physical and mental health can
be estimated [18]. Surveys recalled quality of life within
the previous 4 weeks. One or more items represent the
following eight health concepts: Physical Functioning
(PF), Role Physical (RP), Bodily Pain, General Health,
Vitality (VT), Social Functioning (SF), Role Emotional
(RE), and Mental Health (MH). PF ranges from fulfilling
vigorous activities without limitations to being very
limited in performing all activities including bathing or
dressing. RP and RE deal with problems with work or
other daily activities as a result of physical health or
emotional problems, respectively. SF evaluates interfer-
ence with normal social activities because of physical and
emotional problems. MH notes the frequency of nervous-
ness and depression versus peacefulness, happiness, and
calmness [20] (for more details, see Ware et al. [21]).
Typically, all scores are transformed into a standardized
(0–100) continuous scale, with 50 being the mean and an
SD of 10 [19]. Higher scores represent better health,
function, and overall quality of life.
SF-12 health surveys were evaluated using the SF Health
Outcomes Scoring Software (Qualimetric Inc., Lincoln,
Rhode Island, USA). Statistical significance was tested
using analysis of variance with Greenhouse–Geisser correc-
tion [95% confidence interval (CI)] and two-tailed
Student’s t-test (Stata/IC 10.1 for Windows; StataCorp
LP, College Station, Texas, USA) and Fisher’s exact test
analyzed by SPSS 20.0 (IBM Corporation, Armonk, New




The patients’ median age was 63 years at the time of
CyberKnife radiosurgery (range 27–86 years). Forty-six
patients had uveal melanoma on the right and 45 patients
on the left eye. Forty-eight patients were men and 43
were women. Tumor staging through TNM included
T1 = 12, T2 = 29, T3 = 45, and T4 = 5 tumors. Ciliary
body involvement was present in five patients. Sixty-four
tumors were associated with subretinal fluid. Uveal
melanomas were located in the peripapillary region
(n = 15), at the posterior pole (n = 14), in the midper-
iphery (n = 34), in the periphery (n = 23), and infiltrating
the ciliary body (n = 5). Median best corrected visual
acuity (BCVA) before CyberKnife therapy was 0.5
log(MAR) and decreased to 1.7 log(MAR) after therapy.
Median loss of BCVA was five lines at last follow-up
compared with BCVA before therapy. Table 3 shows the
development of SF-12 overall quality of life 0–100 scoring
at the baseline visit, and at the first and second follow-up.
The categories PF and RP showed a significant decrease
after radiotherapy, whereas MH improved significantly
(P = 0.007, P < 0.0001, and P = 0.023, respectively;
analysis of variance, Greenhouse–Geisser correction,
95% confidence interval for all tables).
Four patients developed metastases throughout the follow-
up period, but the number of these patients was too small
to draw definite conclusions on this subgroup. Relevant
comorbidities were cardiovascular diseases (arrhythmia,
coronary heart disease, status post myocardial infarction,
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or cerebral stroke) in six, arterial hypertension in 13, and
cancer antecedents in nine patients [breast cancer (n = 4),
prostate cancer (n = 1), skin melanoma (n = 1), multiple
myeloma (n = 1), kidney cancer (n = 1), and colon cancer
(n = 1)]. Less commonly, patients presented with diabetes
mellitus II (n = 2), depression (n = 1), Alzheimer’s disease
(n = 1), and chronic hepatitis C (n = 1). Six patients had
undergone previous local therapies before CyberKnife (two
Gamma Knife, two brachytherapy, one surgical resection, one
transpupillary thermotherapy).
Five patients had to undergo retreatment because of local
recurrence after CyberKnife (initial tumor staging T1 = 1,
T2 = 2, T3 = 2).
Subgroup analysis
Secondary glaucoma
Throughout the follow-up period, 30 patients (33.0%)
developed secondary glaucoma that required topical
medication. In addition, three patients needed cyclopho-
tocoagulation, six required application of 1.25 mg intravi-
treal bevacizumab (Avastin) because of neovascular
glaucoma, and one patient required bleb-surgery. Secondary
enucleation was inevitable in three eyes during follow-
up. Table 4 shows the development of SF-12 quality of life
0–100 scoring comparing patients who developed secondary
glaucoma requiring further treatment throughout follow-up
compared with patients who did not need local therapy.
There was a difference of 5.2 points or greater for all items
in the mean baseline score favoring the glaucoma subgroup.
The item MH was significantly higher in the no glaucoma
group at the second follow-up (P = 0.02). In the no
glaucoma group, MH and SF increased significantly
(P = 0.0003 and 0.026). Interestingly, PF decreased
significantly within the same group (P = 0.045). Figures 1
and 2 show the development of MH and SF over time in
both groups. Patients requiring local treatment reported a
significant decrease in RP (P = 0.032).
Table 1 Content of the 12v2 (English version)
Health concept Question Possible answers
Physical Functioning Are you now limited in moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or
playing golf?
Does your health now limit you a lot, limit you a little or not limit you at all?
How about climbing several flights of stairs?
Would you say your health now limits you a lot, limits you a little, or does not limit you at all?
Yes, limited a lot
Yes, limited a little
No, not limited at all
Role Physical During the past 4 weeks, how much of the time have you had any of the following problems with your
work or regular daily activities as a result of your physical health?
How much of the time have you accomplished less than you would like?
How much of the time were you limited in the kind of work or other activities you could do?
None of the time
A little of the time
Some of the time
Most of the time
All of the time
Bodily Pain During the past 4 weeks, how much did pain interfere with your normal work including both outside the











Vitality How much of the time during the past 4 weeks did you have a lot of energy? Would you say y? None of the time
A little of the time
Some of the time
Most of the time
All of the time
Social Functioning During the last 4 weeks, how much of the time has your physical health or emotional problems interfered
with your social activities, like visiting with friends, relatives, etc.?
None of the time
A little of the time
Some of the time
Most of the time
All of the time
Role Emotional During the past 4 weeks, how much of the time have you had any of the following problems with your
work or other daily activities as a result of any emotional problems, such as feeling depressed or
anxious?
How much of the time have you accomplished less than you would like?
How much of the time did you have trouble doing work or other activities as carefully as usual?
None of the time
A little of the time
Some of the time
Most of the time
All of the time
Mental Health How much of the time during the past 4 weeks have you felt calm and peaceful? Would you say y?
How much of the time during the past 4 weeks have you felt downhearted and blue?
None of the time
A little of the time
Some of the time
Most of the time
All of the time
Items related to health concepts.
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There was no significant correlation between tumor size
(T-staging) or tumor location (centrally vs. peripherally)
and the development of secondary glaucoma (P = 0.80
and 0.10, Fisher’s exact test).
Visual acuity
We also carried out subgroup analysis of patients with
BCVA of 0.5 log(MAR) or higher. At this level, stereopsis
and binocularity can be maintained and near-distance
vision is above reading ability, which is important for
everyday life of patients. The influence of these factors
on quality of life was assessed. There was a difference of
6.6 points or greater in PF, RP, Bodily Pain, SF, and RE in
the mean baseline score favoring the subgroup with
higher BCVA. Patients with higher BCVA had signifi-
Table 2 Patient characteristics (n = 91)
Sex Male : female (48 : 43)
Median age (years) 63 (range 27–86)




Subretinal fluid n = 64
Tumor localization Peripapillary (n = 15)
Posterior pole (n = 14)
Midperiphery (n = 34)
Periphery (n = 23)
Ciliary body (n = 5)
Eye Right (n = 46)
Left (n = 45)
Relevant comorbidities Cardiovascular diseases (n = 6)
Arterial hypertension (n = 13)
Cancer antecedents (n = 9)
Diabetes mellitus (n = 2)
Depression (n = 1)
Alzheimer’s disease (n = 1)
Chronic hepatitis C (n = 1)
Development of secondary glaucoma n = 30
BCVAZ0.5log(MAR) At baseline (n = 47)
At second follow-up (n = 17)
Development of metastases n = 4
BCVA, best corrected visual acuity.
Table 3 Overall quality of life
Mean score±SD
Health





PF 82.3±26.7 74.1±29.9 – 8.36 72.7±31.8 – 9.83 0.007
RP 75.8±27.8 70.5±25.1 – 5.62 67.5±27.8 – 8.57 < 0.0001
BP 85.6±26.8 84.8±25.7 – 0.88 81.7±26.1 – 4.02 0.14
GH 58.5±20.9 58.3±18.5 – 0.15 58.2±17.4 – 0.30 0.86
VT 59.6±26.3 63.1±25.1 3.57 57.2±26.1 – 2.33 0.063
SF 72.5±26.3 77.9±25.7 5.59 75.9±26.4 3.57 0.20
RE 73.3±26.4 74.1±27.3 1.07 70.8±26.2 – 2.28 0.27
MH 65.1±22.2 71.5±19.0 6.52 70.1±21.3 5.16 0.023
0–100 Scoring (transformed scores).
Negative numbers indicate worsening from baseline, positive numbers indicate
improvement.
Bold indicates significant values (P < 0.05).
ANOVA, analysis of variance; BP, Bodily Pain; CI, confidence interval; GH,
General Health; MH, Mental Health; PF, Physical Functioning; RE, Role
Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality.
aRepeated-measurements ANOVA, Greenhouse–Geisser correction, 95% CI.
Table 4 Quality of life in glaucoma versus nonglaucoma patients
Score Baseline 1 year 2 years Pa
PF
Glaucoma 86.7±19.4 80.0±26.0 76.9±27.7 0.13
No glaucoma 80.4±29.5 71.8±31.2 70.8±33.5 0.045
Pb 0.34 0.25 0.41
RP
Glaucoma 82.9±22.6 75.0±24.7 72.6±23.7 0.032
No glaucoma 72.8±29.5 68.5±25.2 65.2±29.5 0.079
Pb 0.13 0.28 0.26
BP
Glaucoma 89.2±23.4 83.9±24.7 79.6±26.9 0.13
No glaucoma 84.0±28.2 85.3±26.4 82.6±26.0 0.43
Pb 0.43 0.82 0.62
GH
Glaucoma 63.7±19.3 58.6±16.5 57.2±19.5 0.27
No glaucoma 56.0±21.1 58.2±19.5 58.6±16.5 0.61
Pb 0.10 0.94 0.73
VT
Glaucoma 65.8±27.5 67.3±28.1 55.6±30.5 0.072
No glaucoma 56.5±25.2 61.3±23.7 57.9±24.1 0.21
Pb 0.09 0.31 0.70
SF
Glaucoma 79.2±26.3 77.8±26.3 72.2±27.2 0.22
No glaucoma 69.0±28.5 77.9±25.7 77.5±26.1 0.026
Pb 0.08 0.98 0.39
RE
Glaucoma 79.2±21.1 75.9±29.0 71.3±26.1 0.17
No glaucoma 70.0±28.3 73.3±26.7 70.6±26.4 0.22
Pb 0.09 0.68 0.90
MH
Glaucoma 70.0±20.1 69.2±19.4 62.5±22.2 0.066
No glaucoma 62.5±22.8 72.5±18.8 73.5±20.1 0.0003
Pb 0.10 0.47 0.02
0–100 Scoring (transformed scores).
Bold indicates significant values (P < 0.05).
ANOVA, analysis of variance; BP, Bodily Pain; CI, confidence interval; GH,
General Health; MH, Mental Health; PF, Physical Functioning; RE, Role
Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality.
aRepeated-measurements ANOVA, Greenhouse–Geisser correction, 95% CI.









Baseline 1st follow-up 2nd follow-up
No glaucoma Glaucoma
Development of Mental Health in the glaucoma versus the no glaucoma
group (0–100 scoring).
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cantly higher values of PF and RP at the second follow-up
(P = 0.02, Table 5). Throughout the entire follow-up, RP
decreased significantly in patients whose BCVA de-
creased to below 0.5 log(MAR) (P = 0.013). VT increased
significantly in patients whose BCVA could be preserved
(P = 0.031).
There was no significant correlation between tumor
size nor location and visual outcome throughout the
follow-up period (Fisher’s exact test, P = 0.10 and 0.37,
respectively).
Male versus female comparison
Of the 30 patients developing secondary glaucoma
throughout follow-up, 18 were men and 12 were women.
Of the 17 patients whose BCVA was 0.5 log(MAR) or
higher at the 2-year follow-up, nine were men and eight
were women. As in the complete patient collective, on
comparing quality of life of men versus women, we found
a decrease in the categories PF and RP in both subgroups
at the 2-year follow-up. The decrease in PF was
significant within the male and in RP within the female
subgroup (Fisher’s exact test, P = 0.030 and 0.017,
respectively). After 1 year, MH was significantly higher
within the male subgroup, but no significant difference
could be found at the 2-year follow-up (Table 6).
Discussion
In the past few years, a variety of instruments have been
introduced to measure quality of life and other patient-
based outcomes in healthcare [8]. Treatment success
should not only be measured on medical therapy but also
on how well the medical team can restore the patient’s
peace of mind [14].
The SF-12 is a widely used, practical quality-of-life test
with improved efficiency that is rapid to complete.
A 4-week recall period was proposed because it was
considered that the previous 4 weeks would capture
a more representative and reproducible sample of recent
health, not unduly affected by daily or momentary
fluctuations [22]. In this study, the SF-12 has shown
an acceptable quality of life for uveal melanoma patients
after CyberKnife radiosurgery with an overall decrease of
physical items but stabilization of emotional components
over time. Quality of life was not proven to be dependent
on the type of radiotherapy applied [14]. MH and SF
showed improvement compared with baseline values at
the first and second follow-up examination. In an age-
wise and sex-wise comparable sample, Brandberg
et al. [10] reported reduced quality of life, and emotional
and cognitive functioning at the 1-year follow-up
investigation in both the enucleation and the brachyther-
apy groups. The levels of anxiety, depression, and
emotional problems after radiation therapy or enucleation
remain controversial within the literature [10,23,24], with









Baseline 1st follow-up 2nd follow-up
No glaucoma Glaucoma
Development of Social Functioning in the glaucoma versus the no
glaucoma group (0–100 scoring).
Table 5 Quality of life in patients with BCVAZ0.5 compared
with < 0.5
Score Baseline 1 year 2 years Pa
PF
BCVAZ0.5 91.2±15.2 86.7±18.6 87.5±20.4 0.67
BCVA < 0.5 81.7±25.1 70.0±31.5 67.3±30.6 0.065
Pb 0.17 0.07 0.02
RP
BCVAZ0.5 85.3±23.1 80.4±19.4 81.3±25.0 0.62
BCVA < 0.5 78.7±25.9 68.2±25.3 62.0±26.1 0.013
Pb 0.40 0.13 0.02
BP
BCVAZ0.5 91.2±19.6 90.6±20.2 90.6±22.1 0.96
BCVA < 0.5 84.3±26.1 83.3±28.6 79.9±27.3 0.38
Pb 0.35 0.38 0.10
GH
BCVAZ0.5 64.7±19.1 64.1±15.2 63.8±21.1 0.87
BCVA < 0.5 61.5±21.5 53.7±19.0 59.0±19.9 0.27
Pb 0.62 0.07 0.47
VT
BCVAZ0.5 64.7±19.9 73.4±19.3 70.3±18.8 0.031
BCVA < 0.5 61.1±28.9 61.5±22.1 54.8±28.3 0.49
Pb 0.66 0.09 0.06
SF
BCVAZ0.5 79.4±23.8 87.5±15.8 79.7±26.2 0.33
BCVA < 0.5 71.3±31.5 73.0±25.9 73.1±24.4 0.90
Pb 0.37 0.05 0.41
RE
BCVAZ0.5 80.1±18.8 80.0±23.0 77.3±23.4 0.57
BCVA < 0.5 72.1±27.7 71.2±28.7 66.3±21.1 0.58
Pb 0.30 0.31 0.12
MH
BCVAZ0.5 65.4±19.0 71.1±14.2 78.1±16.8 0.14
BCVA < 0.5 66.2±23.5 71.4±17.9 70.7±20.0 0.46
Pb 0.91 0.96 0.22
0–100 Scoring (transformed scores).
Bold indicates significant values (P < 0.05).
ANOVA, analysis of variance; BCVA, best corrected visual acuity; BP, Bodily
Pain; CI, confidence interval; GH, General Health; MH, Mental Health; PF,
Physical Functioning; RE, Role Emotional; RP, Role Physical; SF, Social
Functioning; VT, Vitality.
aRepeated-measurements ANOVA, Greenhouse–Geisser correction, 95% CI.
bTwo-tailed Student’s t-test, 95% CI.
Quality of life after CyberKnife Klingenstein et al. 485
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
After surgery, the psychological impairment reaches a
maximum at 3 months, when the disease-related limita-
tions become noticeable and patients have difficulty
returning to their lives [19]. Amaro et al. [19] reported
most affection of PF, VT, SF, and MH with a more
balanced quality of life after 1 year. For irradiated
patients, we found a continuous decrease in PF and RP
from the first to the second follow-up, but no dip in
the emotional items SF, MH, or VT. Therefore,
CyberKnife radiosurgery may help attenuate emotional
distress. Possible short-term advantages with respect
to MH after radiation therapy have been published
previously [24].
The decrease in PF and RP might be caused by inclusion
of patients experiencing the development of a secondary
glaucoma or the loss of BCVA over time in Table 3
compared with the subgroup analysis (Tables 4–6).
Physical health measures decrease slightly (and consis-
tently with age) over time [24].
In the glaucoma subgroup, SF decreased, but increased
significantly in the no glaucoma group. SF is solely based
on question 7 of the SF-12 as follows: ‘During the past
4 weeks, how much of the time has your physical health
or emotional problems interfered with your social
activities (like visiting friends, relatives, etc.)?’ (SF-
12v2 Health Survey). The application of topical medica-
tion and the frequent measurements of the intraocular
pressure are time-consuming procedures and a constant
reminder of the primary disease, let alone additional
appointments for laser or intravitreal treatment and fear
for loss of BCVA.
Loss of vision and the ability to drive a car in particular
have a huge impact on quality of life [26]. As preservation
of binocular vision and stereopsis is considered to be of
great importance for a good quality of life, we included a
subgroup analysis with patients who had a final BCVA of
0.5 log(MAR) or higher. These patients also maintained
reading ability of the treated eye, independent of BCVA
of the partner eye. In the literature, visual impairment
is reported by a higher proportion of patients after
radiotherapy, whereas significantly higher proportions of
enucleated patients reported problems walking on
uneven ground and dissatisfaction with their appear-
ance [10]. The COMS QOLS Report No. 3 observed
significant differences favoring patients treated by
brachytherapy for driving at 1 year and for peripheral
vision at 1- and 2-year follow-up [24]. In our study, 17
(37%) of 46 patients initially presenting with a BCVA of
at least 0.5 log(MAR) maintained a BCVA of at least 0.5
log(MAR) and reported a significantly better VT. Loss of
BCVA was reflected in significantly lower PF and RP.
Median loss of visual acuity was five lines at last follow-
up. In comparison, 18% of eyes at the 1-year follow-up
and 34% at the 2-year follow-up resulted in considerable
impairment of BCVA (defined as a loss of six or more lines
of visual acuity from the pretreatment level) after 125I
brachytherapy of medium-sized choroidal melano-
mas [27]. The imbalance of different quality of life
items at baseline favoring the greater than 0.5 log(MAR)
BCVA group is understandable.
Greater tumor prominence, location at the posterior pole,
tumor-associated retinal detachment, or tumors that are
not dome shaped are most likely to have a poor BCVA
outcome within 3 years after therapy [27]. In this study,
we could not prove any significance in terms of the size,
location, and the development of secondary glaucoma or
BCVA.
This study has certain limitations. A longer follow-up is
necessary to evaluate the long-term results of radio-
surgery. Radiation retinopathy is slowly progressive
following radiation exposure [28]. Throughout further
follow-up, patients might develop recurrence or painful
amaurosis requiring enucleation.
Further, comorbidities might act as confounders con-
sidering overall quality of life. It is difficult to evaluate
how far loss in quality of life is correlated with which
comorbidity.
Table 6 Quality of life comparison of male versus female patients
Score Baseline 1 year 2 years Pa
PF
Male 81.8±30.4 73.9±30.4 71.3±33.4 0.030
Female 82.9±22.0 74.4±29.3 72.0±31.8 0.12
Pb 0.84 0.94 0.91
RP
Male 76.8±30.1 69.2±24.6 69.7±27.1 0.17
Female 74.7±25.2 71.6±25.6 64.1±27.9 0.017
Pb 0.72 0.65 0.36
BP
Male 84.9±28.6 84.6±26.4 81.9±25.4 0.66
Female 86.3±24.8 84.9±25.1 78.6±27.9 0.10
Pb 0.80 0.95 0.56
GH
Male 58.1±20.4 59.1±18.8 54.2±21.5 0.29
Female 58.8±21.7 57.6±18.2 60.6±13.9 0.54
Pb 0.87 0.70 0.10
VT
Male 59.9±25.7 65.0±25.2 58.0±26.6 0.06
Female 59.3±27.3 60.1±25.3 57.1±24.9 0.77
Pb 0.92 0.37 0.88
SF
Male 72.4±28.8 78.3±25.9 76.6±27.0 0.35
Female 72.7±27.7 76.7±25.8 75.0±26.2 0.58
Pb 0.96 0.77 0.78
RE
Male 73.4±26.9 78.1±26.1 73.1±28.1 0.13
Female 73.2±26.1 69.3±28.0 66.4±25.5 0.35
Pb 0.97 0.14 0.24
MH
Male 68.0±22.2 75.0±18.1 73.1±21.6 0.06
Female 61.9±22.0 66.5±20.2 67.0±19.5 0.28
Pb 0.20 0.042 0.16
0–100 Scoring (transformed scores).
Bold indicates significant values (P < 0.05).
ANOVA, analysis of variance; BP, Bodily Pain; CI, confidence interval; GH,
General Health; MH, Mental Health; PF, Physical Functioning; RE, Role
Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality.
aRepeated-measurements ANOVA, Greenhouse–Geisser correction, 95% CI.
bTwo-tailed Student’s t-test, 95% CI.
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As the SF-12 Health Survey measures the general outcome
of physical and mental health, it does not focus on
ophthalmological quality-of-life parameters. Considering
cancer as a serious systemic condition, we find it of great
importance to include a core questionnaire such as the SF-12
Health Survey in quality of life evaluation. Questionnaires
that are specifically developed for uveal melanoma patients
take ophthalmological symptoms such as visual impairment,
problems with driving, appearance, and problems reading
more into account (e.g. measure of outcome in ocular
disease) [8] and can be used additionally in future analyses
to optimize the results obtained. Yet, compared with the SF-
12 survey, this may exceed the recommended maximum of
30 items [29], needing more time and concentration for
fulfillment. Additional questionnaires have to be used in
conjunction with the core questionnaire [26] possibly
influencing the patients’ compliance.
We are planning to include the EORTC QLQ-C30
questionnaire in our clinical practice and future analyses.
This has been proven to be a reasonable combination
previously [30]. The survey was specifically developed to
assess the quality of life of cancer patients. The EORTC
QLQ-OPT30 module consists of 30 items for uveal
melanoma patients receiving treatments other than en-
ucleation [26]. Melanoma-associated or treatment-asso-
ciated symptoms such as irritation, visual impairment,
headache, worry about recurrent disease, problems with
driving, problems with appearance, functional problems
because of visual impairment, and reading problems can be
assessed [26]. Yet, surveys generally do not relate solely to
the treated eye and are hence limited in their power.
Because of the subjective nature of quality of life testing, it
is hard to establish equivalence or invariance of items.
Other combinations of quality of life questionnaires used
previously for the assessment of quality of life in uveal
melanoma patients include the SF-36 Health Survey,
the Activities of Daily Vision Scale, the NEI Visual
Function Questionnaire, and the Hospital Anxiety
and Depression Scale [24] or the Hospital Anxiety and
Depression Scale, the EORTC QLQ-C30 (+ 3), the
Impact of Event Scale as well as the Eye Symptom
Questionnaire [10], respectively.
These results provide information about the expected
quality of life concepts after CyberKnife radiosurgery in
uveal melanoma patients. Improvement in MH can be
achieved after radiosurgery and CyberKnife radiosurgery
may contribute toward the attenuation of emotional
distress. Prevention of secondary glaucoma has a sig-
nificant influence on both SF and MH, whereas
preservation of BCVA will affect VT. Emotional stability
throughout the follow-up period contributes positively
toward overall quality of life. Even if the follow-up period
chosen was limited in terms of long-term results, it may
be of great importance, especially for the older patient.
Detailed insights into physical and emotional concepts
allow a more individual treatment decision on the basis of
patients’ preference with respect to visual function,
mental distress, and appearance. Ophthalmologists can
contribute to the process of rehabilitation by being
attentive on returns for consultation.
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